In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Artelo Biosciences (ARTL – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $1.97.
McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, Lineage Therap, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -30.7% and a 20.68% success rate on recommended stocks.
Currently, the analyst consensus on Artelo Biosciences is a Strong Buy with an average price target of $18.33, representing an 830.46% upside. In a report released today, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
ARTL market cap is currently $5.63M and has a P/E ratio of -0.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.
Read More on ARTL:
- Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
- Artelo Biosciences reports Q2 EPS (56c) vs (87c) last year
- Artelo Biosciences to present new mechanism of action data on ART26.12
- Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
- Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
